PCM
ARIA

Piermont Capital Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Piermont Capital Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-81,430
Closed -$671K – 277
2015
Q1 		$671K Buy
81,430
+27,450
+51% +$203K 0.2% 121
2014
Q4 		$371K Hold
53,980
– – 0.13% 141
2014
Q3 		$291K Buy
+53,980
New +$315K 0.11% 168

Other funds holding ARIA

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Piermont Capital Management's ARIA Position: Q2 2015 in Review

Piermont Capital Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q2 2015, closing a stake of 81,430 shares — an estimated $671K sold.

Piermont Capital Management first reported a position in ARIA in Q3 2014 and held it in 3 quarters. The position peaked at $671K in Q1 2015. 177 funds tracked by Wall St. Rank hold ARIA as of Q2 2015.

  • Piermont Capital Management reported no remaining Ariad Pharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • Piermont Capital Management sold 81,430 Ariad Pharmaceuticals Inc shares in Q2 2015, an estimated $671K.
  • Piermont Capital Management first reported a position in Ariad Pharmaceuticals Inc in Q3 2014 and held it in 3 quarters.
  • Piermont Capital Management's Ariad Pharmaceuticals Inc position peaked at $671K in Q1 2015.
  • 177 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q2 2015.

Based on Piermont Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.